Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.62
- Piotroski Score 4.00
- Grade Buy
- Symbol (LUNG)
- Company Pulmonx Corporation
- Price $8.30
- Changes Percentage (0.12%)
- Change $0.01
- Day Low $8.08
- Day High $8.47
- Year High $14.84
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/27/2024
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $20.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.54
- Trailing P/E Ratio -4.51
- Forward P/E Ratio -4.51
- P/E Growth -4.51
- Net Income $-60,843,000
Income Statement
Quarterly
Annual
Latest News of LUNG
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Japan's Nikkei set to plunge 6% with Asia markets on course for mixed open ahead of China data
On May 2, 2024, a cycler passed by the Tokyo Stock Exchange headquarters in Nihonbashi, Tokyo. The Nikkei in Japan was expected to drop by over 6%, with mixed market openings in Asia....
By CNBC | 1 day ago -
A 37-year-old nurse got unusually short of breath on a hike. She had stage 4 lung cancer.
Tiffany Job, a healthy 37-year-old non-smoker, was diagnosed with stage four lung cancer. Despite treatments, the cancer progressed. She shares her journey to raise awareness and funds for research. L...
By Business Insider | 3 days ago -
AbbVie Seeks Accelerated FDA OK of Teliso-V in Non-Small Cell Lung Cancer
AbbVie seeks accelerated FDA approval for teliso-V, an antibody-drug conjugate for c-Met overexpressing non-small cell lung cancer. This treatment targets a specific group of patients with a poor prog...
By MarketWatch | 3 days ago
